What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Prostate cancer
The scientist’s investigation covers issues in Prostate cancer, Internal medicine, Oncology, Cancer and Surgery.
His Prostate cancer research focuses on Prostate-specific antigen in particular.
His study connects Placebo and Internal medicine.
His Oncology research includes themes of Cabazitaxel, Circulating tumor cell, Immunology, Sipuleucel-T and Disease.
His studies deal with areas such as Genome-wide association study and Single-nucleotide polymorphism as well as Cancer.
His Surgery study integrates concerns from other disciplines, such as Watchful waiting, Rectal examination and Urology.
His most cited work include:
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer (1817 citations)
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer (1612 citations)
- Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study (1170 citations)
What are the main themes of his work throughout his whole career to date?
Chris Parker focuses on Prostate cancer, Internal medicine, Oncology, Surgery and Radiation therapy.
Prostate cancer is the subject of his research, which falls under Cancer.
His Prostate-specific antigen, Randomized controlled trial, Chemotherapy and Hazard ratio study, which is part of a larger body of work in Internal medicine, is frequently linked to In patient, bridging the gap between disciplines.
His research in Oncology intersects with topics in Clinical trial, Radium-223, Androgen deprivation therapy, Gynecology and Disease.
His Surgery research incorporates elements of Placebo and Watchful waiting.
Chris Parker interconnects Prostatectomy and Hormone therapy in the investigation of issues within Radiation therapy.
He most often published in these fields:
- Prostate cancer (80.70%)
- Internal medicine (62.01%)
- Oncology (52.77%)
What were the highlights of his more recent work (between 2017-2021)?
- Prostate cancer (80.70%)
- Internal medicine (62.01%)
- Oncology (52.77%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Prostate cancer, Internal medicine, Oncology, Radiation therapy and Prostate.
Prostate cancer is a subfield of Cancer that he explores.
His Cancer study incorporates themes from Biopsy and Magnetic resonance imaging.
As part of his studies on Internal medicine, Chris Parker frequently links adjacent subjects like Life expectancy.
His biological study spans a wide range of topics, including Chemotherapy, Docetaxel, Androgen deprivation therapy, Hazard ratio and Prostate radiotherapy.
His study looks at the relationship between Radiation therapy and topics such as Prostatectomy, which overlap with Urology.
Between 2017 and 2021, his most popular works were:
- Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. (375 citations)
- Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 (333 citations)
- Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. (114 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Prostate cancer
His main research concerns Prostate cancer, Internal medicine, Oncology, Hazard ratio and Androgen deprivation therapy.
His Prostate cancer study deals with the bigger picture of Cancer.
Chris Parker has researched Cancer in several fields, including Biopsy and Radiology.
His study explores the link between Internal medicine and topics such as Placebo that cross with problems in Asymptomatic, Survival rate, Prostvac and Phases of clinical research.
Overall survival, Consensus conference, Abiraterone and Hormone is closely connected to Hormone sensitive prostate cancer in his research, which is encompassed under the umbrella topic of Oncology.
Chris Parker focuses mostly in the field of Hazard ratio, narrowing it down to matters related to Proportional hazards model and, in some cases, Apalutamide.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
